Clinical Scorecard: Efficacy Data on Eye Drop for DME Presented at RWC

At a Glance

Key Highlights

• OCS-01 showed statistically significant improvement in best-corrected visual acuity (BCVA) and reductions in retinal thickness.
• Mean BCVA improvement of 7.2 letters at week 6 for OCS-01 vs 3.1 letters for placebo (P=0.007).
• 27.4% of OCS-01 patients achieved a ≥15-letter BCVA gain by week 12 compared to 7.5% in the placebo group (P=0.009).
• CST decreased by 69.1 µm more in the OCS-01 group at week 6, maintained at 45.6 µm at week 12.
• Increased intraocular pressure (IOP) was noted, with 22 cases in the treatment group.

Guideline-Based Recommendations

Diagnosis

• Assess visual acuity and retinal thickness in patients with diabetic macular edema.

Management

• Consider OCS-01 as a topical treatment option for DME, especially for patients seeking alternatives to intravitreal injections.

Monitoring & Follow-up

• Monitor intraocular pressure in patients receiving OCS-01.

Risks

• Increased intraocular pressure may occur; monitor and manage as necessary.

Patient & Prescribing Data

Patients with diabetic macular edema, both treatment-naïve and previously treated.

OCS-01 demonstrated rapid and sustained improvements in vision and retinal thickness.

Clinical Best Practices

• Utilize OCS-01 in a structured treatment plan for DME, considering patient history and treatment status.
• Ensure regular follow-up to monitor visual acuity and retinal thickness.

References

• 2025 Retina World Congress Presentation